Journal of Vaccines & Vaccination

Immune Response Patterns Following Modern Vaccine Formulations

Kiran Dev Reddy^* Department of Immunobiology, National Institute of Life Sciences, Hyderabad, India
^*Correspondence: Kiran Dev Reddy, Department of Immunobiology, National Institute of Life Sciences, Hyderabad, India, Email:

Received: 01-Jun-2025, Manuscript No. JVV-25-31341; Editor assigned: 03-Jun-2025, Pre QC No. JVV-25-31341 (PQ); Reviewed: 17-Jun-2025, QC No. JVV-25-31341; Revised: 24-Jun-2025, Manuscript No. JVV-25-31341 (R); Published: 30-Jun-2025, DOI: 10.35248/2157-7560.25.16.611

Description

Vaccine immunogenicity refers to the ability of a vaccine to stimulate an immune response that can protect an individual from infection or disease. This response involves a coordinated activation of various immune cells, signaling molecules and memory components that together determine the level and duration of protection. Over time, the understanding of how vaccines interact with the human immune system has expanded significantly, leading to improved formulations and evaluation methods. When a vaccine is introduced into the body, antigenpresenting cells such as dendritic cells process the antigen and display it on their surface [1]. This interaction triggers T lymphocytes, which then support the activation of B lymphocytes responsible for antibody production. The quality of this response depends on several factors, including antigen structure, delivery system and host-related characteristics such as age, genetics and nutritional status. One important factor influencing immunogenicity is the design of the antigen itself [2]. Protein-based vaccines, inactivated pathogens and nucleic acid-based platforms each stimulate the immune system in different ways. For example, messenger Ribonucleic Acid (mRNA) vaccines direct host cells to produce the antigen internally, which often results in strong cellular and humoral responses. In contrast, inactivated vaccines primarily stimulate antibody production and may require additional doses or adjuvants to achieve sufficient protection [3].

Adjuvants are substances included in vaccines to enhance immune activation. They work by increasing antigen uptake, prolonging antigen presence and stimulating innate immune pathways. Common adjuvants include aluminum salts and oil-inwater emulsions. These components influence cytokine production and help shape the type of immune response generated, such as whether it is more antibody-driven or cellmediated [4]. Another key aspect is the route of administration. Intramuscular injections are the most common method, but alternative routes such as intranasal or oral delivery can influence mucosal immunity. Mucosal immune responses are particularly important for pathogens that enter through respiratory or gastrointestinal pathways. By targeting these entry points, vaccines can reduce transmission in addition to preventing disease. The timing and number of doses also affect immunogenicity [5]. Primary vaccination primes the immune system, while booster doses reinforce memory responses. The interval between doses can influence the magnitude and durability of immunity. Short intervals may lead to rapid protection, whereas longer intervals can sometimes enhance long-term memory.

Population variability plays a significant role in vaccine response. Infants and elderly individuals often show different immune profiles compared to healthy adults [6]. In older adults, immune responses may be reduced due to immunosenescence, a gradual decline in immune function. This has led to the development of higher-dose or adjuvanted vaccines specifically designed for older populations. Environmental and lifestyle factors also contribute to immunogenicity. Nutritional deficiencies, chronic diseases and exposure to environmental stressors can alter immune responsiveness. Additionally, prior exposure to similar pathogens may enhance or interfere with vaccine-induced responses through mechanisms such as cross-reactivity [7]. Evaluation of vaccine immunogenicity typically involves measuring antibody levels, assessing neutralizing activity and analyzing T-cell responses. Advanced laboratory techniques such as flow cytometry and Enzyme-Linked Immunosorbent Assay (ELISA) are commonly used for these assessments. More recently, systems biology approaches have been applied to study global immune responses, integrating data from multiple biological layers to provide a comprehensive understanding [8].

Safety is closely linked with immunogenicity. A vaccine must produce a sufficient immune response without causing significant adverse effects. Balancing these aspects is essential during vaccine development and clinical testing. Regulatory agencies require extensive evaluation of both parameters before approval. Recent advancements in biotechnology have enabled rapid development of vaccines during public health emergencies [9]. The global response to COVID-19 demonstrated how modern platforms can be adapted quickly to address emerging threats. These developments have also highlighted the importance of continuous monitoring and adaptation to maintain vaccine effectiveness. Future research is focusing on improving the precision of vaccine design, identifying correlates of protection and enhancing responses in populations with weaker immunity. The integration of computational modeling and experimental data is expected to refine vaccine strategies further [10].

Conclusion

In conclusion, vaccine immunogenicity is influenced by a complex interaction of biological, technological and environmental factors. Advances in antigen design, delivery systems and immune monitoring have significantly improved the ability to generate effective vaccines. Continued research and innovation will play an essential role in addressing existing challenges and preparing for future infectious threats.

References

1. Dinc G, Ulman YI. The introduction of variolation ‘A La Turca’to the West by Lady Mary Montagu and Turkey's contribution to this. Vaccine. 2007;25(21):4261-4265.

   [CrossRef] [Google Scholar] [PubMed]

2. Riley AG, Voehler D, Mitrovich R, Carias C, Ollendorf DA, Nelson KL, Synnott PG, Eiden AL. Documenting the Full Value of Vaccination: A Systematic Review of Value Frameworks. Value in Health. 2024;27(9):1289-1299.

   [CrossRef] [Google Scholar] [PubMed]

3. Zeinab D, Shahin N, Fateme M, Saeed BF. Economic evaluation of vaccination against COVID�19: A systematic review. Health Sci Rep. 2024;7(2): 1871.

   [CrossRef] [Google Scholar] [PubMed]

4. Cho JY, Lee H, Wannaadisai W, Vietri J, Chaiyakunapruk N. Systematic literature review of cost-effectiveness analyses of adult 15-and 20-valent pneumococcal vaccines. Vaccine. 2025 ;46:126656.

   [CrossRef] [Google Scholar] [PubMed]

5. Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Imm. 2010;33(4):451-463.

   [CrossRef]  [Google Scholar] [PubMed]

6. Zhang Y, Gao J, Xu W, Huo X, Wang J, Xu Y, Ding W, Guo Z, Liu R. Advances in protein subunit vaccines against H1N1/09 influenza. Front Immunol. 2024; 15:1499754.

   [CrossRef] [Google Scholar] [PubMed]

7. Thomas SJ, Yoon IK. A review of Dengvaxia®: development to deployment. Hum Vaccin Immunother. 2019;15(10):2295-2314.

   [CrossRef] [Google Scholar] [PubMed]

8. Slota M, Lim JB, Dang Y, Disis ML. ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines. 2011;10(3):299-306.

   [CrossRef] [Google Scholar] [PubMed]

9. Moser JM, Sassano ER, Leistritz DC, Eatrides JM, Phogat S, Koff W, Drake III DR. Optimization of a dendritic cell-based assay for the in vitro priming of naive human CD4+ T cells. J Immunol Methods. 2010;353(1-2):8-19.

   [CrossRef]  [Google Scholar] [PubMed]

10. Duffy D. Milieu interieur: Defining the boundaries of a healthy immune response for improved vaccination strategies. Hum Vaccin Immunother. 2018;14(9):2217-2221.

    [CrossRef] [Google Scholar] [PubMed]